Methoxyetomidate Explained

Cas Number:	1567838-90-7
Pubchem:	74766803
Synonyms:	ET-26
Iupac Name:	2-methoxyethyl (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylate
C:	15
H:	18
N:	2
O:	3
Smiles:	[C@H](C)(N1C(C(OCCOC)=O)=CN=C1)C2=CC=CC=C2
Stdinchi:	InChI=1S/C15H18N2O3/c1-12(13-6-4-3-5-7-13)17-11-16-10-14(17)15(18)20-9-8-19-2/h3-7,10-12H,8-9H2,1-2H3/t12-/m1/s1
Stdinchikey:	JJSJTELMIQBHDE-GFCCVEGCSA-N

Methoxyetomidate is an investigational anesthetic agent being developed by Jinzhou Ahon Pharmaceutical Co., Ltd. It is a short-acting intravenous anesthetic that acts as a positive allosteric modulator of GABAA receptors.^{[1] [2]} As of 2024, methoxyetomidate is undergoing Phase 3 clinical trials for use in anesthesia.^[3]

Notes and References

1. Web site: ET-26 Methoxyetomidate Hydrochloride Development Information . Synapse by Patsnap . 2024-11-23.
2. Wang B, Chen S, Yang J, Yang L, Liu J, Zhang W . ET-26 hydrochloride (ET-26 HCl) has similar hemodynamic stability to that of etomidate in normal and uncontrolled hemorrhagic shock (UHS) rats . PLOS ONE . 12 . 8 . e0183439 . 2017 . 28813523 . 5557577 . 10.1371/journal.pone.0183439 . free . 2017PLoSO..1283439W .
3. Web site: ET-26 Clinical Trials Overview . Synapse by Patsnap . 2024-11-23.